The chairman of Cambridge Therapeutics, John Klein has facilitated FDA approval of more than 300 generic drugs throughout his extensive career in the pharmaceutical industry. John Klein is also the chairman and CEO of Bilogix, LLC, in Alpine, NJ.

Bilogix is an enterprise performance management (EPM) firm, meaning that it offers proprietary services designed to boost business clients’ operational performance and overall efficiency with an emphasis on information-technology infrastructure. EPM processes help measure, analyze, and estimate organizational performance and add value to businesses by directing the appropriate resources to achieve desired objectives. While EPM shares some commonalities with data processing tools like analytics and business intelligence (BI), they differ in their approach.

Most notably, BI and analytics tools focus on highlighting relevant information pertaining to daily operations so leaders can make informed decisions. In this way, they are generally reactive. Conversely, EPM tools are proactive. This is because they allow organizations to assess overall performance and make necessary changes based on information and data as it becomes available. Both BI and EPM have their benefits, and companies are increasingly leveraging both to track and refine operations.